Toxicities Associated with PARP Inhibitors in Ovarian Cancer

In an interview with Targeted Oncology, Craig Sauter, MD, discusses available treatments for patients with central nervous system lymphoma and research that will provide more developments moving forward in this space.

In season 2, episode 6 of Targeted Talks, Alexander B. Olawaiye, MD leads a discussion with Haider S. Mahdi, MD, about the modern approaches to treating cervical and endometrial cancers.

In an interview, Krisda Chaiyachati, MD, MPH, discussed some of the social determinants of health for patients with cancer and some of the challenges patients undergoing treatment face, including transportation insecurity.

Sarah M. Temkin, MD leads discussion with Daphne B. Stewart, MD, around targeted therapies in ovarian cancer, whether offered in the academic or community setting.

Toripalimab with bevacizumab and platinum-based chemotherapy showed promising response and disease control rates in patients with refractory, recurrent and metastatic cervical cancer.

In updated findings of the ENGOT-OV16/NOVA trial, final overall survival data of niraparib maintenance therapy showed a benefit for patients with recurrent ovarian cancer; however, mature data showed no significant benefit. In updated findings of the ENGOT-OV16/NOVA trial, final overall survival data of niraparib maintenance therapy showed a benefit for patients with recurrent ovarian cancer; however, mature data showed no significant benefit.